Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
adverse drug reactions
Biotech
Genfit ends liver failure program over phase 2 safety signal
Genfit has stopped development of VS-01 in acute-on-chronic liver failure after a patient suffered a serious adverse event in a phase 2 trial.
Nick Paul Taylor
Sep 22, 2025 5:14am
Lipid may hold the key to new liver drugs
Jun 7, 2022 6:00am
Aligos calls it quits on 2nd med after 'unexpected' reactions
Mar 22, 2022 10:40am
Redx cleared to start Wnt cancer trial again after safety scare
Jan 21, 2019 9:05am
Redx pauses WNT cancer trial following adverse events
Mar 29, 2018 3:35am
Seattle Genetics stops all trials of '33A blood cancer drug
Jun 19, 2017 9:37am
